Ildr2 antagonists and combinations thereof
AssigneesBayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Compugen Ltd.
InventorsLars RÖSE, Uwe GRITZAN, Julia HÜTTER, Spencer LIANG, Andrew POW, John HUNTER, Ofer LEVY, Ilan VAKNIN
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel pharmaceutical combination comprising an ILDR2 antagonist according to any of the aforementioned claims, plus one or more other therapeutically active compounds, and to novel specific ILDR2 antagonists.
Claims22
A pharmaceutical combination comprising an ILDR2 antagonist plus optionally one or more other therapeutically active compounds.
An anti-ILDR2 antibody, or a fragment or derivative thereof, or a modified antibody format, all of which having ILDR2 binding properties, which comprises at least the 3 CDR heavy chain sequences:
- SEQ ID No 1 CDR1 HC
- SEQ ID No 2 CDR2 HC
- SEQ ID No 3 CDR3 HC
- or which comprises at least the three CDR light chain sequences:
- SEQ ID No 4 CDR1 LC
- SEQ ID No 5 CDR2 LC
- SEQ ID No 6 CDR3 LC.
(canceled)
An anti-ILDR2 antibody, or a fragment or derivative thereof, or a modified antibody format, all of which having ILDR2 binding properties, which comprises at least one combination of three CDR heavy chain sequences, selected from a group consisting of:
- SEQ ID No 18-20,
- SEQ ID No 24-26,
- SEQ ID No 30-32, and/or
- SEQ ID No 36-38
- or which comprises at least one combination of three CDR light chain sequences, selected from a group consisting of:
- SEQ ID No 21-23,
- SEQ ID No 27-29,
- SEQ ID No 33-35 and/or
- SEQ ID No 39-41.
(canceled)
An anti-ILDR2 antibody, or a fragment or derivative thereof, or a modified antibody format, all of which having ILDR2 binding properties, which comprises at least one heavy chain or light chain variable region sequence that is 95% identical, preferably 96 or even 97% identical, more preferably 98% or even 99% identical, and most preferably 100% to a sequence selected from the group consisting of:
- SEQ ID No 9,
- SEQ ID No 10,
- SEQ ID No 11,
- SEQ ID No 12,
- SEQ ID No 13,
- SEQ ID No 14,
- SEQ ID No 15, and/or
- SEQ ID No 16.
An anti-ILDR2 antibody, or a fragment or derivative thereof, or a modified antibody format, all of which having ILDR2 binding properties, which comprises at least one heavy chain or light chain sequence that is 95% identical, preferably 96 or even 97% identical, more preferably 98% or even 99% identical, and most preferably 100% to a sequence selected from the group consisting of:
- SEQ ID No 44,
- SEQ ID No 45,
- SEQ ID No 46,
- SEQ ID No 47,
- SEQ ID No 48,
- SEQ ID No 49,
- SEQ ID No 50, and/or
- SEQ ID No 51.
21-23. (canceled)
Dependencies are inferred from the claim text.